Literature DB >> 10791994

Proinflammatory consequences of transgenic fas ligand expression in the heart.

D P Nelson1, E Setser, D G Hall, S M Schwartz, T Hewitt, R Klevitsky, H Osinska, D Bellgrau, R C Duke, J Robbins.   

Abstract

Expression of Fas ligand (FasL) renders certain tissues immune privileged, but its expression in other tissues can result in severe neutrophil infiltration and tissue destruction. The consequences of enforced FasL expression in striated muscle is particularly controversial. To create a stable reproducible pattern of cardiomyocyte-specific FasL expression, transgenic (Tg) mice were generated that express murine FasL specifically in the heart, where it is not normally expressed. Tg animals are healthy and indistinguishable from nontransgenic littermates. FasL expression in the heart does result in mild leukocyte infiltration, but despite coexpression of Fas and FasL in Tg hearts, neither myocardial tissue apoptosis nor necrosis accompanies the leukocyte infiltration. Instead of tissue destruction, FasL Tg hearts develop mild interstitial fibrosis, functional changes, and cardiac hypertrophy, with corresponding molecular changes in gene expression. Induced expression of the cytokines TNF-alpha, IL-1beta, IL-6, and TGF-beta accompanies these proinflammatory changes. The histologic, functional, and molecular proinflammatory consequences of cardiac FasL expression are transgene-dose dependent. Thus, coexpression of Fas and FasL in the heart results in leukocyte infiltration and hypertrophy, but without the severe tissue destruction observed in other examples of FasL-directed proinflammation. The data suggest that the FasL expression level and other tissue-specific microenvironmental factors can modulate the proinflammatory consequences of FasL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10791994      PMCID: PMC378206          DOI: 10.1172/JCI8212

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Transgenic remodeling of the regulatory myosin light chains in the mammalian heart.

Authors:  J Gulick; T E Hewett; R Klevitsky; S H Buck; R L Moss; J Robbins
Journal:  Circ Res       Date:  1997-05       Impact factor: 17.367

Review 2.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

Review 3.  Fas-ligand: privilege and peril.

Authors:  D R Green; C F Ware
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

Authors:  J Allison; H M Georgiou; A Strasser; D L Vaux
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.

Authors:  S M Kang; D B Schneider; Z Lin; D Hanahan; D A Dichek; P G Stock; S Baekkeskov
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

6.  Selective inhibition of protein kinase C isozymes by Fas ligation.

Authors:  C Y Chen; D V Faller
Journal:  J Biol Chem       Date:  1999-05-28       Impact factor: 5.157

7.  The role of Fas in autoimmune diabetes.

Authors:  A V Chervonsky; Y Wang; F S Wong; I Visintin; R A Flavell; C A Janeway; L A Matis
Journal:  Cell       Date:  1997-04-04       Impact factor: 41.582

8.  Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153.

Authors:  B Brenner; U Koppenhoefer; C Weinstock; O Linderkamp; F Lang; E Gulbins
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

9.  Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis.

Authors:  C Giordano; G Stassi; R De Maria; M Todaro; P Richiusa; G Papoff; G Ruberti; M Bagnasco; R Testi; A Galluzzo
Journal:  Science       Date:  1997-02-14       Impact factor: 47.728

10.  Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice.

Authors:  N Itoh; A Imagawa; T Hanafusa; M Waguri; K Yamamoto; H Iwahashi; M Moriwaki; H Nakajima; J Miyagawa; M Namba; S Makino; S Nagata; N Kono; Y Matsuzawa
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

View more
  19 in total

Review 1.  Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis.

Authors:  M W Cunningham
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

3.  Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload.

Authors:  Cornel Badorff; Hartmut Ruetten; Sven Mueller; Meike Stahmer; Doris Gehring; Frank Jung; Christian Ihling; Andreas M Zeiher; Stefanie Dimmeler
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

4.  Effects of Fas-ligand overexpression on alveolar type II cell growth kinetics in perinatal murine lungs.

Authors:  Monique E de Paepe; Sheila A Haley; Zacharie Lacourse; Quanfu Mao
Journal:  Pediatr Res       Date:  2010-07       Impact factor: 3.756

Review 5.  TNF revisited: osteoprotegerin and TNF-related molecules in heart failure.

Authors:  Thor Ueland; Arne Yndestad; Christen P Dahl; Lars Gullestad; Pål Aukrust
Journal:  Curr Heart Fail Rep       Date:  2012-06

6.  Ectopic expression of Fas Ligand on cardiomyocytes renders cardiac allografts resistant to CD4(+) T-cell mediated rejection.

Authors:  Robert J Plenter; Todd J Grazia; David P Nelson; Martin R Zamora; Ronald G Gill; Biagio A Pietra
Journal:  Cell Immunol       Date:  2014-12-06       Impact factor: 4.868

7.  The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy.

Authors:  Junichi Sadoshima; Olivier Montagne; Qian Wang; Guiping Yang; Jill Warden; Jing Liu; Gen Takagi; Vijaya Karoor; Chull Hong; Gary L Johnson; Dorothy E Vatner; Stephen F Vatner
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

8.  Nitric oxide and promotion of cardiac myocyte apoptosis.

Authors:  Péter Andréka; Thanh Tran; Keith A Webster; Nanette H Bishopric
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

9.  Tumor necrosis factor receptor-associated factor 2 signaling provokes adverse cardiac remodeling in the adult mammalian heart.

Authors:  Vijay G Divakaran; Sarah Evans; Veli K Topkara; Abhinav Diwan; Jana Burchfield; Feng Gao; Jianwen Dong; Huei-Ping Tzeng; Natarajan Sivasubramanian; Philip M Barger; Douglas L Mann
Journal:  Circ Heart Fail       Date:  2013-03-14       Impact factor: 8.790

10.  The Fas system confers protection against alveolar disruption in hyperoxia-exposed newborn mice.

Authors:  Quanfu Mao; Sravanthi Gundavarapu; Chintan Patel; Amy Tsai; Francois I Luks; Monique E De Paepe
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-27       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.